Biomarin Pharmaceutical Inc (BMRN)
Cash conversion cycle
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 808.91 | 771.55 | 730.70 | 702.13 | 667.91 | 674.72 | 643.53 | 631.98 | 614.19 | 602.50 | 573.56 | 461.62 | 488.84 | 486.33 | 517.80 | 675.07 | 674.85 | 690.75 | 656.56 | 659.03 |
| Days of sales outstanding (DSO) | days | 95.20 | 97.47 | 92.40 | 101.95 | 102.79 | 81.76 | 76.60 | 89.45 | 83.89 | 74.58 | 74.80 | 81.89 | 79.64 | 89.78 | 82.46 | 76.73 | 81.61 | 81.30 | 92.07 | 90.63 |
| Number of days of payables | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash conversion cycle | days | 904.10 | 869.02 | 823.09 | 804.08 | 770.70 | 756.48 | 720.13 | 721.42 | 698.08 | 677.08 | 648.37 | 543.51 | 568.48 | 576.11 | 600.26 | 751.80 | 756.46 | 772.05 | 748.63 | 749.66 |
March 31, 2024 calculation
Cash conversion cycle = DOH + DSO – Number of days of payables
= 808.91 + 95.20 – —
= 904.10
The cash conversion cycle of Biomarin Pharmaceutical Inc has shown fluctuations over the past few quarters. The trend indicates that the company's ability to convert its resources efficiently into cash has varied.
In the most recent quarter, ending on March 31, 2024, the company's cash conversion cycle was 904.10 days, representing an increase compared to the previous quarter. This extended duration suggests that Biomarin Pharmaceutical Inc took longer to convert its investments, inventory, and accounts receivable into cash during this period.
Looking back over the past few quarters, there have been fluctuations in the cash conversion cycle, with some quarters showing improvements and others showing increases. The variability in the cash conversion cycle indicates potential challenges in managing working capital efficiently.
Overall, Biomarin Pharmaceutical Inc should closely monitor its cash conversion cycle and work towards optimizing its operating cycle, payment terms, and inventory management to improve cash flow efficiency and overall financial performance.
Peer comparison
Mar 31, 2024